Cargando…

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses

Detalles Bibliográficos
Autores principales:	Wetzler, M, Kantarjian, H M, Nicolini, F E, Lipton, J H, Akard, L, Baccarani, M, Khoury, H J, Li, E, Munteanu, M, Cortes, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735071/ https://www.ncbi.nlm.nih.gov/pubmed/26657200 http://dx.doi.org/10.1038/bcj.2015.104

Ejemplares similares

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
por: Chen, Yaoyu, et al.
Publicado: (2014)

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
por: Kulkarni, Hemant, et al.
Publicado: (2012)

Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
por: ZHANG, LINA, et al.
Publicado: (2016)

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
por: Winer, Eric S., et al.
Publicado: (2018)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma
por: Li, Ling, et al.
Publicado: (2021)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice
por: Chen, Yaoyu, et al.
Publicado: (2009)

Logistic Regression—Explanation and Use
por: Hall, G H, et al.
Publicado: (1994)

Practical guide to logistic regression
por: Hilbe, Joseph M
Publicado: (2016)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
por: Müller, Martin C., et al.
Publicado: (2023)

Chronic Obstructive Pulmonary Disease: Novel Genes Detection with Penalized Logistic Regression
por: Gohari, Kimiya, et al.
Publicado: (2023)

Applied logistic regression
por: Hosmer, David W, et al.
Publicado: (2013)

Applied logistic regression /
por: Hosmer, David W.
Publicado: (2000)

On the consequences of model misspecification in logistic regression.
por: Begg, M D, et al.
Publicado: (1990)

Logistic regression : a self-learning text /
por: Kleinbaum, David G.
Publicado: (2002)

Logistic regression : a self-learning text /
por: Kleinbaum, David G.
Publicado: (1994)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Logistic Regression Analysis of Clinical Characteristics for Differentiation of Chronic Obstructive Pulmonary Disease Severity
por: Guo, Shuaixing
Publicado: (2023)

Predictors of hospital admission when presenting with acute-on-chronic breathlessness: Binary logistic regression
por: Hutchinson, Ann, et al.
Publicado: (2023)

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2018)

Endogeneity in Logistic Regression Models
por: Avery, George
Publicado: (2005)

Understanding logistic regression analysis
por: Sperandei, Sandro
Publicado: (2014)

Logistic Regression in Medical Research
por: Schober, Patrick, et al.
Publicado: (2021)

Primer on binary logistic regression
por: Harris, Jenine K
Publicado: (2021)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Potential Misinterpretation of Treatment Effects Due to Use of Odds Ratios and Logistic Regression in Randomized Controlled Trials
por: Knol, Mirjam J., et al.
Publicado: (2011)

Inconsistency Between Univariate and Multiple Logistic Regressions
por: WANG, Hongyue, et al.
Publicado: (2017)

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
por: Gong, Z, et al.
Publicado: (2017)

Calculus of thought: neuromorphic logistic regression in cognitive machines
por: Rice, Daniel M
Publicado: (2014)

Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis
por: Harrell, Frank E
Publicado: (2001)

Noncollapsibility and its role in quantifying confounding bias in logistic regression
por: Schuster, Noah A., et al.
Publicado: (2021)

Log-linear models and logistic regression
por: Christensen, Ronald, 1951-
Publicado: (1997)

Statistics review 14: Logistic regression
por: Bewick, Viv, et al.
Publicado: (2005)

Purposeful selection of variables in logistic regression
por: Bursac, Zoran, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3b3jvjl4g1rno38elcfnancduj